Valuation: Onconic Therapeutics Inc.

Market Cap 697B 515M 453M 429M 388M 730M 49.34B 740M 5.14B 1.98B 25.22B 1.93B 1.89B 80.86B P/E 2024
-16.5x
P/E 2025 56.2x
Enterprise Value 644B 476M 419M 397M 358M 675M 45.61B 684M 4.75B 1.83B 23.32B 1.79B 1.75B 74.76B EV / Sales 2024
9.02x
EV / Sales 2025 15.3x
Free-Float
50.62%
Yield 2024 *
-
Yield 2025 -
1 day+0.13%
1 week+4.21%
Current month-14.86%
1 month+3.93%
3 months+9.64%
6 months-33.41%
Current year-21.48%
1 week 15,150
Extreme 15150
16,430
1 month 14,420
Extreme 14420
18,620
Current year 8,790
Extreme 8790
28,900
1 year 8,790
Extreme 8790
28,900
3 years 3,137.5
Extreme 3137.5
28,900
5 years 3,137.5
Extreme 3137.5
28,900
10 years 3,137.5
Extreme 3137.5
28,900
Manager TitleAgeSince
Chief Executive Officer 59 01/01/2020
Director of Finance/CFO 50 01/01/2020
Chief Tech/Sci/R&D Officer 59 -
Director TitleAgeSince
Director/Board Member 50 01/01/2020
Director/Board Member 59 01/01/2020
Director/Board Member 44 26/03/2024
Date Insider Type Main position Quantity % Market Cap. Importance
22/4/25 Exercice 50,000 0.4595%
18/4/25 Exercice

Chief Technology Officer

12,500 0.1149%
17/4/25 Exercice

Chief Financial Officer

18,100 0.1663%
Change 5-day change 1-year change 3-year change Capi.($)
+0.13%+4.21%+16.73% - 513M
+4.16%-0.30%+58.96%+94.17% 71.53B
-0.19%+1.32%+37.20%+81.33% 60.12B
-1.51%+2.39%+9.10%+36.79% 48.85B
+0.67%+0.98%+42.40%+39.51% 44.28B
+1.16%+8.45%+342.96%+690.45% 43.83B
+1.42%+1.54%+8.78%+107.62% 41.53B
-0.67%-0.45%+4.47%+46.37% 30.13B
+4.77%+6.46%+41.54%+22.78% 27.98B
+0.30%-2.20%-19.63%+356.21% 25.25B
Average +1.05%+0.85%+54.25%+163.91% 39.4B
Weighted average by Cap. +1.24%+0.63%+63.40%+154.85%

Financials

2024 2025
Net sales 14.84B 10.95M 9.65M 9.14M 8.25M 15.55M 1.05B 15.75M 109M 42.08M 537M 41.13M 40.24M 1.72B 53.39B 39.42M 34.71M 32.89M 29.69M 55.96M 3.78B 56.68M 393M 151M 1.93B 148M 145M 6.19B
Net income -8.09B -5.97M -5.26M -4.98M -4.5M -8.48M -573M -8.59M -59.64M -22.95M -293M -22.43M -21.94M -939M 15.78B 11.65M 10.26M 9.72M 8.78M 16.54M 1.12B 16.76M 116M 44.76M 571M 43.75M 42.8M 1.83B
Net Debt -42.69B -31.52M -27.75M -26.29M -23.74M -44.74M -3.02B -45.32M -315M -121M -1.54B -118M -116M -4.95B -52.61B -38.84M -34.2M -32.4M -29.25M -55.14M -3.72B -55.85M -388M -149M -1.9B -146M -143M -6.1B
Logo Onconic Therapeutics Inc.
Onconic Therapeutics Inc is a Korea-based company principally engaged in the new drugs research and development business. The Company mainly develops new drugs and treatments in the acid-related diseases, digestive diseases and anticancer fields based on small molecules. The Company’s products include acid-related disease treatment drug Zastaprazan and synthetic lethal deoxyribonucleic acid (DNA) damage repair inhibitor anticancer drug Nesuparib.
Employees
-
Date Price Change Volume
30/09/26 ₩15,350.00 +0.13% 137,919
29/09/26 ₩15,330.00 -4.07% 242,765
28/09/26 ₩15,980.00 +5.62% 604,734
23/09/26 ₩15,130.00 +2.72% 372,242
22/09/26 ₩14,730.00 -2.13% 163,340
  1. Stock Market
  2. Stocks
  3. A476060 Stock